Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

Delenex Therapeutics AG. (2/1/11). "Press Release: Delenex Therapeutics Complements Its Management. Delenex Appoints Eric de La Fortelle as CEO and Jakob Schlapbach as CFO". Schlieren.

Region Region Schlieren ZH
  Country Switzerland
Organisations Organisation Delenex Therapeutics AG
  Today Cell Medica Switzerland AG
  Group Cell Medica (Group)
  Organisation 2 Cytos Biotechnology AG
  Today Kuros Biosciences AG (SIX: KURN)
  Group Kuros (Group)
Products Product PENTRA® antibody (fragment)
  Product 2 PENTRA® antibody (fragment) technology platform
Persons Person de La Fortelle, Eric (Delenex 201102– CEO before Roche)
  Person 2 Schlapbach, Jakob (Delenex 201012– CFO before 10y+ Cytos Biotechnology CFO before Ascom CFO)
     


Today, Delenex Therapeutics (" Delenex ") announced the appointments of Eric de La Fortelle as new CEO, and Jakob Schlapbach as new CFO.

Eric de La Fortelle brings significant experience from the pharmaceutical industry to Delenex. He served previously in two senior roles at F. Hoffmann-La Roche ("Roche"). Beginning in 2005, Eric was Global Head, External Research and Technologies, leading a ten-person group responsible for establishing and managing around fifty strategic alliances each year in early-stage products and technologies. In 2008 and 2009, he also served as Global Head, Emerging Technologies.

Eric de La Fortelle's scientific work contributed to the field of protein structure determination. The SHARP software, of which he was the initial lead author, contributed to the resolution of more than a thousand protein structures by X-ray crystallography.

Eric de La Fortelle is a graduate from Ecole Centrale de Paris, holds a Ph.D. in structural biology from Paris XI University and an MBA from INSEAD.

Jakob Schlapbach joined Delenex in December, 2010, as CFO. Mr. Schlapbach brings more than thirty years of banking and industrial financing experience to the company. He has been CFO of Cytos Biotechnology for more than ten years until mid-2010 and held the same position with Ascom group between 1994 and 2000. At Cytos Biotechnology he has been instrumental in raising funds in the amount of CHF 262 million from institutional and private investors and played a key role in the going public of Cytos Biotechnology. He was elected "CFO of the Year" in 2002 by the renowned Swiss newspaper Finanz und Wirtschaft.

Jakob Schlapbach holds an MBA from INSEAD and an economics degree from University of Berne (lic.rer.pol.).

Thomas Hecht, chairman of Delenex said: "We are pleased and proud to have attracted two managers of such a high calibre to Delenex. I am convinced that Eric with his 1 of 3 international experience and strong business development & licensing background has the skillset to lead Delenex to become a significant player in the field of antibody fragments. I am also looking forward to working again with Jakob, a seasoned CFO with a long career in finance and in the biotech area, having broad experience in financial transactions."

Eric de La Fortelle mentioned: "I am looking forward joining Delenex at this stage, where it will move its lead project towards the clinic while building a strong pipeline from its proven platform technology."

"I am excited about the opportunity to work for Delenex and to support the team in all financial matters", Jakob Schlapbach added.
_______________________________

About Delenex Therapeutics AG

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. These antibody fragments called PENTRA® fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. The PENTRA® technology is clinically validated and delivers antibody therapeutics exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Delenex is a spin off from ESBATech AG before its acquisition by Alcon, Inc. in September 2009 and operates out of laboratories and offices in Schlieren/Zürich.

Message from 1.02.2011

For further information please contact:
Dr. Eric de La Fortelle, Phone +41-44-730 5180

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Cell Medica (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81




» top